Hyperuricemia and incident heart failure

Circulation: Heart Failure

Volumn 2, Issue 6, 2009, Pages 556-562

  Krishnan, Eswar ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biological markers; Heart failure; Hyperuricemia; Incidence; Prospective studies; Risk; Uric acid

Indexed keywords

ALLOPURINOL; ANTIHYPERTENSIVE AGENT; URIC ACID;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HEART FAILURE; HUMAN; HYPERURICEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; URIC ACID BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HUMANS; HYPERURICEMIA; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; URIC ACID; YOUNG ADULT;

EID: 77953663063     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.108.797662     Document Type: Article

References (47)

1. Gwadry-Sridhar FH, Flintoft V, Lee DS, Lee H, Guyatt GH. A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med. 2004;164: 2315-2320.
2. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am. 2004;88:1145-1172.
3. Thomas RD, Newill A, Morgan DB. The cause of the raised plasma urea of acute heart failure. Postgrad Med J. 1979;55:10-14.
4. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJ. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18: 858-865.
5. Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J. 1999;13:682-685.
6. Pascual-Figal DA, Hurtado-Martinez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2007;9:518-524.
7. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991-1997.
8. Niizeki T, Takeishi Y, Arimoto T, Okuyama H, Nozaki N, Hirono O, Tsunoda Y, Watanabe T, Nitobe J, Miyashita T, Takahashi H, Koyama Y, Kubota I. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. J Cardiol. 2006;47:219-228.
9. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Yamagishi M, Tei C, Hiraoka H, Sonoda M, Tsuchihashi K, Shimoyama N, Honda T, Ogata Y, Matsui K, Ogawa H; Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol. 2005;96:489-495.
10. Olexa P, Olexova M, Gonsorcik J, Tkac I, Kisel'ova J, Olejnikova M. Uric acid-a marker for systemic inflammatory response in patients with congestive heart failure? Wien Klin Wochenschr. 2002;114:211-215.
11. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, Poole-Wilson PA, Coats AJ. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998;19:1814-1822.
12. Doehner W, von Haehling S, Anker SD. Uric acid as a prognostic marker in acute heart failure-new expectations from an old molecule. Eur J Heart Fail. 2007;9:437-439.
13. Kittleson MM, St John ME, Bead V, Champion HC, Kasper EK, Russell SD, Wittstein IS, Hare JM. Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart. 2007;93:365-367.
14. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation. 2003;107:1951-1953.
15. Samuelsson O, Wilhelmsen L, Pennert K, Berglund G. Angina pectoris, intermittent claudication and congestive heart failure in middle-aged male hypertensives. Development and predictive factors during long-term antihypertensive care. The Primary Preventive Trial, Goteborg, Sweden. Acta Med Scand. 1987;221:23-32.
16. Strasak A, Ruttmann E, Brant L, Kelleher C, Klenk J, Concin H, Diem G, Pfeiffer K, Ulmer H. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83, 683 Austrian men. Clin Chem. 2008; 54:273-284.
17. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci. 1963;107: 539-556.
18. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41:237-242.
19. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446.
20. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. J Am Med Assoc. 1996; 275:1557-1562.
21. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118:816-826.
22. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688-2696.
23. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168:1104-1110.
24. Avram Z, Krishnan E. Hyperuricaemia-where nephrology meets rheumatology. Rheumatology (Oxford). 2008;47:960-964.
25. Krishnan E. Gout and coronary artery disease: epidemiologic clues. Curr Rheumatol Rep. 2008;10:249-255.
26. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49:298-303.
27. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
28. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16: 3553-3562.
29. Johnson RJ, Rodriguez-Iturbe B, Kang DH, Feig DI, Herrera-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens. 2005;18: 431-440.
30. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25:39-42.
31. Alcaino H, Greig D, Chiong M, Verdejo H, Miranda R, Concepcion R, Vukasovic JL, Diaz-Araya G, Mellado R, Garcia L, Salas D, Gonzalez L, Godoy I, Castro P, Lavandero S. Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail. 2008;10:646-651.
32. Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF II, Kullo IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens. 2007;20:83-89.
33. Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, Lauretani F, Bandinelli S, Senin U, Ferrucci L. Uric acid and inflammatory markers. Eur Heart J. 2006;27:1174-1181.
34. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23:1835-1839.
35. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67: 960-966.
36. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum. 1991;34:141-145.
37. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28-33.
38. Tomita M, Mizuno S, Yamanaka H, Hosoda Y, Sakuma K, Matuoka Y, Odaka M, Yamaguchi M, Yosida H, Morisawa H, Murayama T. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol. 2000;10:403-409.
39. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39:1227-1233.
40. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. J Am Med Assoc. 2008;300:924-932.
41. Doehner W, Anker SD. Uric acid in chronic heart failure. Semin Nephrol. 2005;25:61-66.
42. Reyes AJ. The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure. Eur J Heart Fail. 2005;7: 461-467.
43. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlof B. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041-1049.
44. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105: 2619-2624.
45. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart. 2002;87: 229-234.
46. Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown J, Perez NG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail. 2006;12:491-498.
47. Cleland JG, Coletta AP, Clark AL. Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF. Eur J Heart Fail. 2006;8:764-766.